Xue Bai1,2,3, Xiaobo Yang1,2, Liangcai Wu1,2,4,5, Bangyou Zuo1, Jianzhen Lin1, Shanshan Wang1, Jin Bian1, Xinting Sang1, Yungang He2, Zhen Yang1,2, Haitao Zhao1. 1. Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing 100730, China. 2. Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China. 3. Department of Radiology, Nanfang Hospital, First Clinical College of Northern Medical University, Guangzhou 510515, China. 4. Key Laboratory of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, Beijing 100190, China. 5. Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090, China.
Abstract
BACKGROUND: The cancer molecular targeted therapy has achieved unprecedented progress in the past decade and is thought to be the most promising direction for cancer treatment in future. As the fast growing of the clinical trials of targeted anticancer agents for different cancer types, it is critical to collect and integrate such information to guide clinical practice. METHODS: We constructed the Cancer Molecular Targeted Therapy database (CMTTdb) to store and retrieve molecular targeted therapy data about randomized clinical trials (RCTs) of targeted agents and also accompanied targets, biomarkers, targeted cancer subtypes, etc. RESULTS: Different with some existing resources, CMTTdb particularly focuses on clinical application of the trails. Design of the trails, such as treatment modalities (monotherapy or combination with other therapies), as well as results on clinical efficacy parameters, adverse events are also collected. In this current version, CMTTdb contains data for 1,088 clinical trials which cover 165 agents, 80 targets, 15 cancer types (95 molecular subtypes and 56 histological or cytological subtypes) from public literatures. This database is freely available at http://www.biosino.org/CMTTdb. A user-friendly web interface was designed so that these data can be easily retrieved. CONCLUSIONS: CMTTdb will be a valuable source for providing access to information of clinical trials on the rapidly growing number of novel targeted agent and be useful in guiding oncologists for the optimization of the therapy strategy for cancer treatment. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: The cancer molecular targeted therapy has achieved unprecedented progress in the past decade and is thought to be the most promising direction for cancer treatment in future. As the fast growing of the clinical trials of targeted anticancer agents for different cancer types, it is critical to collect and integrate such information to guide clinical practice. METHODS: We constructed the Cancer Molecular Targeted Therapy database (CMTTdb) to store and retrieve molecular targeted therapy data about randomized clinical trials (RCTs) of targeted agents and also accompanied targets, biomarkers, targeted cancer subtypes, etc. RESULTS: Different with some existing resources, CMTTdb particularly focuses on clinical application of the trails. Design of the trails, such as treatment modalities (monotherapy or combination with other therapies), as well as results on clinical efficacy parameters, adverse events are also collected. In this current version, CMTTdb contains data for 1,088 clinical trials which cover 165 agents, 80 targets, 15 cancer types (95 molecular subtypes and 56 histological or cytological subtypes) from public literatures. This database is freely available at http://www.biosino.org/CMTTdb. A user-friendly web interface was designed so that these data can be easily retrieved. CONCLUSIONS: CMTTdb will be a valuable source for providing access to information of clinical trials on the rapidly growing number of novel targeted agent and be useful in guiding oncologists for the optimization of the therapy strategy for cancer treatment. 2019 Annals of Translational Medicine. All rights reserved.
Authors: Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-14 Impact factor: 4.254
Authors: Stephen L Mathias; Jarrett Hines-Kay; Jeremy J Yang; Gergely Zahoransky-Kohalmi; Cristian G Bologa; Oleg Ursu; Tudor I Oprea Journal: Database (Oxford) Date: 2013-06-21 Impact factor: 3.451
Authors: Nikolai Hecker; Jessica Ahmed; Joachim von Eichborn; Mathias Dunkel; Karel Macha; Andreas Eckert; Michael K Gilson; Philip E Bourne; Robert Preissner Journal: Nucleic Acids Res Date: 2011-11-08 Impact factor: 16.971
Authors: David S Wishart; Yannick D Feunang; An C Guo; Elvis J Lo; Ana Marcu; Jason R Grant; Tanvir Sajed; Daniel Johnson; Carin Li; Zinat Sayeeda; Nazanin Assempour; Ithayavani Iynkkaran; Yifeng Liu; Adam Maciejewski; Nicola Gale; Alex Wilson; Lucy Chin; Ryan Cummings; Diana Le; Allison Pon; Craig Knox; Michael Wilson Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971